James Smith, MD
Hospitalist · Newnan, GANPI 1053395129
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 293 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 34 manufacturers, the largest accounting for just 11.1% — the pattern of someone who eats at a lot of different presentations. Among hospitalist clinicians in GA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 293 payments — averaging $16.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$530
- Lilly USA, LLC$485
- AstraZeneca$475
- AbbVie$371
- Astellas Pharma US Inc$350
- Boehringer Ingelheim$328
- plus $2K from 28 others
What the payments were for
- Food & beverage$4,755100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 44 | $530 |
| Lilly USA, LLC | 33 | $485 |
| AstraZeneca | 29 | $475 |
| AbbVie | 24 | $371 |
| Astellas Pharma US Inc | 20 | $350 |
| Boehringer Ingelheim | 15 | $328 |
| GSK | 21 | $322 |
| Sanofi-aventis U.S. LLC | 14 | $267 |
| Pfizer | 13 | $216 |
| Johnson & Johnson | 13 | $208 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 10 | $175 |
| Novartis | 11 | $174 |
| Amgen | 6 | $85 |
| Dexcom, Inc. | 5 | $82 |
| Xeris Pharmaceuticals, Inc. | 3 | $70 |
| Exact Sciences | 5 | $70 |
| Otsuka America Pharmaceutical, Inc. | 3 | $68 |
| Bayer | 3 | $66 |
| Inspire Medical Systems, Inc. | 2 | $63 |
| Sumitomo Pharma America, Inc. | 3 | $58 |
| Shield Therapeutics Inc | 2 | $46 |
| Edwards Lifesciences | 1 | $29 |
| Merck | 2 | $27 |
| Axsome Therapeutics, Inc. | 1 | $21 |
| Radius Health, Inc. | 1 | $20 |
| Antares Pharma, Inc. | 1 | $19 |
| Eisai Inc. | 1 | $19 |
| Amneal Pharmaceuticals LLC | 1 | $18 |
| Kowa Pharmaceuticals America, Inc. | 1 | $18 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $17 |
| Amarin Pharma, Inc. | 1 | $17 |
| Phathom Pharmaceuticals, Inc. | 1 | $16 |
| Idorsia Pharmaceuticals US Inc | 1 | $13 |
| Medtronic | 1 | $12 |
How this compares
$4,755 in reported general payments places this provider in the 95th percentile of 812 hospitalist providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 299 | $412,117 |
| JardianceEmpagliflozin | 196 | $248,000 |
| MounjaroTirzepatide | 133 | $175,729 |
| EliquisApixaban | 191 | $170,992 |
| JanuviaSitagliptin Phosphate | 62 | $74,307 |
| FarxigaDapagliflozin Propanediol | 71 | $65,681 |
| XareltoRivaroxaban | 41 | $58,369 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 42 | $35,892 |
| TrulicityDulaglutide | 24 | $34,102 |
| CreonLipase/Protease/Amylase | 12 | $28,776 |
| MyrbetriqMirabegron | 27 | $16,207 |
| VascepaIcosapent Ethyl | 20 | $9,605 |
| Ajovy AutoinjectorFremanezumab-Vfrm | 11 | $9,272 |
| Rosuvastatin Calcium | 559 | $9,133 |
| Atorvastatin Calcium | 902 | $8,131 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Novolog | $530 | $418,472325 claims |
| Boehringer IngelheimJardiance, Synjardy Xr | $328 | $255,927209 claims |
| Lilly USA, LLCMounjaro, Trulicity | $485 | $209,831157 claims |
| PfizerEliquis | $216 | $170,992191 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort, Nexium | $475 | $83,661122 claims |
| MerckJanuvia | $27 | $74,30762 claims |
| Johnson & JohnsonXarelto | $208 | $58,36941 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $322 | $39,74153 claims |
| AbbVieCreon | $371 | $28,77612 claims |
| Astellas Pharma US IncMyrbetriq | $350 | $16,20727 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $18 | $5,093525 claims |
| Sanofi-aventis U.S. LLCLantus | $267 | $5,03318 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 812 hospitalist providers in Georgia.
Other hospitalist in Newnan
- Stanley SmithNewnan$6K
- Sri Krishna MukkamalaCumming$240K
- Annie ParkCanton$19K
- Philippa AmeneGainesville$11K
- Anna SikodGainesville$9K
- Emilio LacayoAtlanta$9K
- Mukesh KumarAtlanta$6K
- Alfred RathinamAthens$6K
- Amaka EzimoraAtlanta$6K
- Anum NiaziMacon$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.